Duality Biotherapeutics, Inc. repurchased 10.00 thousand ordinary shares on 2 November 2026 via on-market transactions, paying HKD 98.55–99.60 per share for a volume-weighted average of HKD 99.21. The total consideration reached HKD 0.99 million, and the repurchased stock has been retained as treasury shares.
Simultaneously, 10.20 thousand new shares were issued through the exercise of options granted under the company’s Pre-IPO Equity Incentive Plan at an exercise price of HKD 9.85 per share.
After accounting for both actions: • Issued shares excluding treasury shares edged up by 0.20 thousand to 91.06 million. • Treasury shares increased to 0.85 million. • Total issued shares rose to 91.90 million.
Under the repurchase mandate approved on 26 June 2026, the company is authorized to buy back up to 9.06 million shares. Cumulative repurchases now stand at 0.52 million shares, or 0.58 % of the share count when the mandate was granted. A 30-day moratorium on new share issues or treasury-share sales remains in force through 1 December 2026, in line with Hong Kong listing rules.
Comments